Company intelligence / Profile preview
NephRx Corporation
Kalamazoo, Michigan, United Statesnephrx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NX001 demonstrated promising activity in improving kidney function in preclinical models of acute renal failure[1]. The company initiated Phase I trials of NX001 for prevention of delayed graft function in kidney transplant patients[4].
- Therapeutic areas
- NephrologyGastroenterology
- Modalities
- Peptides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on NephRx Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NephRx Corporation.